Psychiatric safety concerns lead to Acomplia suspension
This article was originally published in Scrip
Executive Summary
The European Medicines Agency has recommended that Sanofi-Aventis's obesity treatment Acomplia (rimonabant) be temporarily suspended across the EU owing to concerns over psychiatric safety, and the company says it will comply with the recommendation.